Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.67 |
| ▸ | ACE | P12821 | 4/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanyltyrosine SCHEMBL31255162 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL29803603 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL4282059 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| SCHEMBL29511618 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| SCHEMBL29531478 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| SCHEMBL8695556 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| SCHEMBL8695549 | 1.00 | MME (0.67) | MMEACEOPRD1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL25307390 | 0.99 | MME (0.66) | MMEACEOPRD1OPRM1OPRK1 | |
| SCHEMBL8665210 | 0.97 | MME (0.64) | MMEACEOPRD1OPRM1OPRK1 | |
| SCHEMBL8665198 | 0.97 | MME (0.64) | MMEACEOPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454527-B2 | Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer | IZVARINO FARMA AB (SE) | 2025-10-28 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20220281852-A1 | CONJUGATE MONOMETHYL AURISTATIN E TO OBTAIN A COMPOSITION FOR TREATMENT OF PROSTATE CANCER | IZVARINO FARMA AB (SE) | 2022-09-08 | — | — | US | claimed |
| CN-106459151-A | Cyclic dipeptide-containing composition | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-105407907-A | Uric acid level lowering agent | SUNTORY HOLDINGS LTD | 2016-03-16 | — | — | CN | claimed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-12454527-B2 | Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer | IZVARINO FARMA AB (SE) | 2025-10-28 | — | — | US | disclosed |
| CN-119970736-A | Synthesis method of histone deacetylase 4 small molecule inhibitor and application of inhibitor in vascular endothelial aging resistance | 澳门科技大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119033924-B | Development and application of porcine infectious pleuropneumonia subunit vaccine | 吉林大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-118813570-A | Flavone glycosyltransferase, mutant and application thereof | 井冈山大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-118440915-A | Manganese peroxidase ThMnP for degrading vomitoxin, coding gene and application | 四川农业大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2006016705-A1 | THE USE OF PHOSPHOKETOLASE FOR PRODUCING USEFUL METABOLITES | AJINOMOTO CO., INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
| US-20060019355-A1 | L-Amino acid-producing microorganism and method for producing L-amino acid | AJINOMOTO CO., INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| WO-2005073390-A2 | L-AMINO ACID-PRODUCING MICROORGANISM AND METHOD FOR PRODUCING L-AMINO ACID | AJINOMOTO CO., INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
| JP-2003246796-A | NOVEL UNDARIA PEPTIDE, L-PHENYLALANYL-L-TYROSINE, AND ANTIHYPERTENSIVE AGENT | SUETSUNA YOKO | 2003-09-02 | — | — | JP | disclosed |
| US-4097608-A | Anti-ulcerous tyrosine derivatives | DAIICHI SEIYAKU CO., LTD. (JA) | 1978-06-27 | — | — | US | disclosed |
| US-4057629-A | ANTIULCER | DAIICHI SEIYAKU CO., LTD. (JA) | 1977-11-08 | — | — | US | disclosed |
| US-4025644-A | ANTIULCER | DAIICHI SEIYAKU CO., LTD. (JA) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454527-B2 | Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer | FOLH1, AURKA, MAN2B2 | MME 156/4885ACE 2643/4885OPRD1 2877/4885 |
| US-20220281852-A1 | CONJUGATE MONOMETHYL AURISTATIN E TO OBTAIN A COMPOSITION FOR TREATMENT OF PROSTATE CANCER | FOLH1, AURKA, MAN2B2 | MME 156/4885ACE 2643/4885OPRD1 2877/4885 |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | MME 4394/4885ACE 3845/4885OPRD1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.